The characterisation of molecular abnormalities in patients with lung cancers has led to the development of a number of targeted therapies, mainly based on mutations in the EGFR, ALK or KRAS genes
Authors
The characterisation of molecular abnormalities in patients with lung cancers has led to the development of a number of targeted therapies, mainly based on mutations in the EGFR, ALK or KRAS genes